comparemela.com

Latest Breaking News On - Sectoral asset management inc - Page 4 : comparemela.com

Bain Capital Life Sciences Investors LLC Purchases 2,359,793 Shares of Annexon, Inc (NASDAQ:ANNX)

Bain Capital Life Sciences Investors LLC grew its position in shares of Annexon, Inc. (NASDAQ:ANNX – Free Report) by 41.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,061,719 shares of the company’s stock after buying an additional 2,359,793 shares during the period. […]

Arvinas (NASDAQ:ARVN) Shares Down 10 3%

Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) was down 10.3% on Monday . The company traded as low as $29.72 and last traded at $29.72. Approximately 456,905 shares changed hands during trading, a decline of 36% from the average daily volume of 719,479 shares. The stock had previously closed at $33.14. Wall Street Analyst Weigh […]

Verastem (NASDAQ:VSTM) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Verastem (NASDAQ:VSTM – Free Report) in a report issued on Tuesday morning, Benzinga reports. The brokerage currently has a $17.50 target price on the biopharmaceutical company’s stock. A number of other research firms also recently commented on VSTM. Royal Bank of Canada reaffirmed an outperform rating […]

Royal Bank of Canada Trims Verastem (NASDAQ:VSTM) Target Price to $16 00

Verastem (NASDAQ:VSTM – Free Report) had its target price decreased by Royal Bank of Canada from $32.00 to $16.00 in a research note released on Tuesday morning, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the biopharmaceutical company’s stock. Several other brokerages also recently commented on VSTM. HC Wainwright reiterated a […]

Alliance Global Partners Cuts Verastem (NASDAQ:VSTM) Price Target to $20 00

Verastem (NASDAQ:VSTM – Free Report) had its target price trimmed by Alliance Global Partners from $34.00 to $20.00 in a research note released on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also issued reports on VSTM. Royal Bank of Canada […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.